LY-3873862

N/A

Report date: 2024/12/18 13:39:48
NME

Base Information

Drug NameLY-3873862
Drug Alias NameLY-3873862
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNAD(+) hydrolase SARM1 inhibitors
TargetsNAD(+) hydrolase SARM1
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A